-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec today, Novartis announced that the US FDA has approved Scemblix (asciminib) for the treatment of two different indications of chronic myeloid leukemia (CML)
.
The FDA has accelerated the approval of Scemblix for the treatment of Philadelphia (Ph) chromosome-positive CML patients in the chronic phase who have previously received two or more tyrosine kinase inhibitors (TKI) treatments
.
At the same time, the FDA fully approved it for the treatment of the above-mentioned patients with the T315I mutation
.
The press release pointed out that Scemblix is the first CML therapy combined with the myristoyl pocket of ABL1, providing an important new treatment option for patients who are resistant or intolerant to current TKI therapies
.
CML is a malignant myeloproliferative tumor that occurs in pluripotent hematopoietic stem cells.
It is characterized by a significant increase in granulocytes in the peripheral blood.
In some CML patients, Ph chromosome and/or BCR-ABL fusion genes can be found
.
For many patients, current therapies are limited by intolerance and drug resistance, and patients with T315I mutations are resistant to most TKIs, so the risk of disease progression increases
.
Scemblix is an allosteric inhibitor against ABL1, which inhibits the activity of BCR-ABL1 by binding to the myristoyl pocket of ABL1
.
Because its binding site with BCR-ABL1 is different from common TKI, it may solve the problem of TKI resistance and intolerance in the later treatment of CML patients
.
▲Scemblix's mechanism of action (picture source: reference [2]) This approval is based on the results of a phase 3 clinical trial and a phase 1 clinical trial
.
The results of the phase 3 clinical trial showed that Scemblix almost doubled the patient's major molecular response rate (MMR) in 24 weeks compared with the active control (25.
5% vs.
13.
2%, p=0.
029)
.
Moreover, the proportion of patients who stopped receiving treatment due to adverse reactions was one third of the control group (7% vs.
25%)
.
"If patients are intolerant or resistant to existing therapies, CML may become difficult to treat
.
" said Dr.
Michael J.
Mauro of Memorial Sloan Kettering Cancer Center.
"Scemblix has given us the fight against this blood cancer.
Innovative methods to help solve the challenges faced by treated patients
.
"Reference: [1] FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia.
Retrieved October 29, 2021, from https:// 2021/10/29/2323914/0/en/FDA-approves-Novartis-Scemblix-asciminib-with-novel-mechanism-of-action-for-the-treatment-of-chronic-myeloid-leukemia.
html[2] Hughes, et al.
(2019).
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
NEJM, DOI: 10.
1056/NEJMoa1902328 Disclaimer: WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is only for information exchange.
Purpose, the opinions in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views
in the
article .
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
.
The FDA has accelerated the approval of Scemblix for the treatment of Philadelphia (Ph) chromosome-positive CML patients in the chronic phase who have previously received two or more tyrosine kinase inhibitors (TKI) treatments
.
At the same time, the FDA fully approved it for the treatment of the above-mentioned patients with the T315I mutation
.
The press release pointed out that Scemblix is the first CML therapy combined with the myristoyl pocket of ABL1, providing an important new treatment option for patients who are resistant or intolerant to current TKI therapies
.
CML is a malignant myeloproliferative tumor that occurs in pluripotent hematopoietic stem cells.
It is characterized by a significant increase in granulocytes in the peripheral blood.
In some CML patients, Ph chromosome and/or BCR-ABL fusion genes can be found
.
For many patients, current therapies are limited by intolerance and drug resistance, and patients with T315I mutations are resistant to most TKIs, so the risk of disease progression increases
.
Scemblix is an allosteric inhibitor against ABL1, which inhibits the activity of BCR-ABL1 by binding to the myristoyl pocket of ABL1
.
Because its binding site with BCR-ABL1 is different from common TKI, it may solve the problem of TKI resistance and intolerance in the later treatment of CML patients
.
▲Scemblix's mechanism of action (picture source: reference [2]) This approval is based on the results of a phase 3 clinical trial and a phase 1 clinical trial
.
The results of the phase 3 clinical trial showed that Scemblix almost doubled the patient's major molecular response rate (MMR) in 24 weeks compared with the active control (25.
5% vs.
13.
2%, p=0.
029)
.
Moreover, the proportion of patients who stopped receiving treatment due to adverse reactions was one third of the control group (7% vs.
25%)
.
"If patients are intolerant or resistant to existing therapies, CML may become difficult to treat
.
" said Dr.
Michael J.
Mauro of Memorial Sloan Kettering Cancer Center.
"Scemblix has given us the fight against this blood cancer.
Innovative methods to help solve the challenges faced by treated patients
.
"Reference: [1] FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia.
Retrieved October 29, 2021, from https:// 2021/10/29/2323914/0/en/FDA-approves-Novartis-Scemblix-asciminib-with-novel-mechanism-of-action-for-the-treatment-of-chronic-myeloid-leukemia.
html[2] Hughes, et al.
(2019).
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
NEJM, DOI: 10.
1056/NEJMoa1902328 Disclaimer: WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is only for information exchange.
Purpose, the opinions in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views
in the
article .
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
